Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings
ByAinvest
Sunday, Aug 10, 2025 2:42 am ET1min read
MMM--
Sangamo Biosciences (SGMO)
Sangamo Biosciences, a biotechnology company focused on genomic medicines, has a Moderate Buy consensus with a $4.10 price target. The company's stock has been volatile, with a 3m6m1y return of -56.36% and a YTD return of -56.36%. Analysts cite the company's partnerships with major pharmaceutical firms and its pipeline of innovative therapies as positive factors. However, they also highlight significant financial challenges, including declining revenue, a weakening balance sheet, and negative cash flows. The company's reliance on securing partnerships for sustainability is a key concern [1].
Pliant Therapeutics (PLRX)
Pliant Therapeutics, a biopharmaceutical company, has a Hold consensus with a $3.67 price target. The company's stock has shown a 3m6m1y return of -14.85% and a YTD return of -14.85%. Analysts acknowledge the company's potential in the development of novel therapeutics but express caution due to its early-stage clinical trials and limited revenue. The company's focus on rare diseases and oncology is seen as a promising area, but the risks associated with clinical development and regulatory uncertainty are significant [2].
Zimmer Biomet Holdings (ZBH)
Zimmer Biomet Holdings, a medical device company, has a Hold consensus with a $107.62 price target. The company's stock has shown a 3m6m1y return of 14.43% and a YTD return of 14.43%. Analysts praise the company's strong market position and robust pipeline of innovative medical devices. However, they also note the competitive landscape and the potential for regulatory changes to impact the company's financial performance. The company's focus on orthopedics and spinal devices is seen as a key growth driver, but the risks associated with market saturation and pricing pressures are significant [3].
References:
[1] https://www.tipranks.com/stocks/sgmo/stock-analysis
[2] https://www.tipranks.com/stocks/plrx/stock-analysis
[3] https://www.tipranks.com/stocks/zbh/stock-analysis
PLRX--
SGMO--
ZBH--
Analysts weigh in on Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX), and Zimmer Biomet Holdings (ZBH). Sangamo Biosciences has a Moderate Buy consensus with a $4.10 price target. Pliant Therapeutics has a Hold consensus with a $3.67 price target. Zimmer Biomet Holdings has a Hold consensus with a $107.62 price target.
Analysts have provided their insights on the financial prospects of Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX), and Zimmer Biomet Holdings (ZBH). Here's a breakdown of their consensus ratings and price targets.Sangamo Biosciences (SGMO)
Sangamo Biosciences, a biotechnology company focused on genomic medicines, has a Moderate Buy consensus with a $4.10 price target. The company's stock has been volatile, with a 3m6m1y return of -56.36% and a YTD return of -56.36%. Analysts cite the company's partnerships with major pharmaceutical firms and its pipeline of innovative therapies as positive factors. However, they also highlight significant financial challenges, including declining revenue, a weakening balance sheet, and negative cash flows. The company's reliance on securing partnerships for sustainability is a key concern [1].
Pliant Therapeutics (PLRX)
Pliant Therapeutics, a biopharmaceutical company, has a Hold consensus with a $3.67 price target. The company's stock has shown a 3m6m1y return of -14.85% and a YTD return of -14.85%. Analysts acknowledge the company's potential in the development of novel therapeutics but express caution due to its early-stage clinical trials and limited revenue. The company's focus on rare diseases and oncology is seen as a promising area, but the risks associated with clinical development and regulatory uncertainty are significant [2].
Zimmer Biomet Holdings (ZBH)
Zimmer Biomet Holdings, a medical device company, has a Hold consensus with a $107.62 price target. The company's stock has shown a 3m6m1y return of 14.43% and a YTD return of 14.43%. Analysts praise the company's strong market position and robust pipeline of innovative medical devices. However, they also note the competitive landscape and the potential for regulatory changes to impact the company's financial performance. The company's focus on orthopedics and spinal devices is seen as a key growth driver, but the risks associated with market saturation and pricing pressures are significant [3].
References:
[1] https://www.tipranks.com/stocks/sgmo/stock-analysis
[2] https://www.tipranks.com/stocks/plrx/stock-analysis
[3] https://www.tipranks.com/stocks/zbh/stock-analysis
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet